SPAGO Pix

SPAGO Imaging develops a novel and proprietary tumor selective contrast agent for MRI, SPAGO Pix, which has the potential to significantly improve visualization of most soft tissue tumors.

Low specificity (false positive findings) has a significant clinical impact causing increased patient suffering and added costs due to unnecessary biopsies and supplementary procedures. Early and accurate diagnosis is vital to ensure treatment efficiency and increase long term patient survival.

SPAGO Pix has unique features with potential to;

• Enable detection of small tumors
• Reduce the number of false positives

It is a gadolinium-free nanoparticle based contrast agent with exceptionally high relaxivity (signal strength) that selectively accumulates in tumor tissue via passive tumor targeting (EPR effect). To date, excellent contrast between tumor and surrounding tissue has been obtained in preclinical proof of concept studies which indicates the potential as a clinical diagnostic. Further efficacy- and toxicity studies are ongoing and GLP toxicity studies will be initiated in 2012.

The focus for SPAGO Pix is initially breast cancer expanding to other soft tissue tumors.